Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

A Novel Niosomal Combination of Selenium Coupled with Glucantime against Leishmania tropica

  • Mostafavi, Mahshid (Leishmaniasis Research Center, Kerman University of Medical Sciences) ;
  • Khazaeli, Payam (Department of Pharmaceutics, Faculty of Pharmacy, Kerman University of Medical Sciences) ;
  • Sharifi, Iraj (Leishmaniasis Research Center, Kerman University of Medical Sciences) ;
  • Farajzadeh, Saeedeh (Department of Pediatric Dermatology, Kerman University of Medical Sciences) ;
  • Sharifi, Hamid (HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences) ;
  • Keyhani, Alireza (Leishmaniasis Research Center, Kerman University of Medical Sciences) ;
  • Parizi, Maryam Hakimi (Leishmaniasis Research Center, Kerman University of Medical Sciences) ;
  • Kakooei, Sina (Leishmaniasis Research Center, Kerman University of Medical Sciences)
  • Received : 2018.10.27
  • Accepted : 2019.01.22
  • Published : 2019.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

There is no effective treatment modality available against different forms of leishmaniasis. Therefore, the aim of this study was to improve the penetration and efficacy of selenium and glucantime coupled with niosomes and compared them with their simple forms alone on in vitro susceptibility assays. In this study, the niosomal formulations of selenium and in combination with glucantime were prepared. The size and morphology of the niosomal formulations were characterized and the effectivity of the new formulation was also evaluated using in vitro MTT assay, intra-macrophage model, and gene expression profile. From the results obtained, no cytotoxicity effect was observed for niosomal and simple forms of drugs, as alone or in combination. Niosomal formulations of the drugs significantly showed more inhibitory effects ($P{\leq}0.001$) than the simple drugs when the selectivity index was considered. The gene expression levels of Interleukin (IL-10) significantly decreased, while the level of IL-12 and metacaspase significantly increased ($P{\leq}0.001$). The results of the present study showed that selenium plus glucantime niosome possess a potent anti-leishmanial effect and enhanced their lethal activity as evidenced by the in vitro experiments.

Keywords

References

  1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671. https://doi.org/10.1371/journal.pone.0035671
  2. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006; 22: 552-557. https://doi.org/10.1016/j.pt.2006.09.004
  3. Karimi A, Hanafi-Bojd AA, Yaghoobi-Ershadi MR, Akhavan AA, Ghezelbash Z. Spatial and temporal distributions of phlebotomine sand flies (Diptera: Psychodidae), vectors of leishmaniasis, in Iran. Acta Trop 2014; 132: 131-139. https://doi.org/10.1016/j.actatropica.2014.01.004
  4. Aflatoonian MR, Sharifi I, Hakimi Parizi M, Fekri AR, Aflatoonian B, Sharifi M, Khosravi A, Khamesipour A, Sharifi H. A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in south eastern Iran. PLoS One 2014; 9: e89043. https://doi.org/10.1371/journal.pone.0089043
  5. Sharifi I, Aflatoonian MR, Fekri AR, Hakimi Parizi M, Aghaei Afshar A, Khosravi A, Sharifi F, Aflatoonian B, Khamesipour A, Dowlati Y, Modabber F, Nadim A. A comprehensive review of cutaneous leishmaniasis in kerman province, southeastern irannarrative review article. Iran J Public Health 2015; 44: 299-307.
  6. Saghafipour A, Rassi Y, Abai MR, Oshaghi MA, Farzinnia B, Mostafavi R, Karimian F. Outbreak of zoonotic cutaneous leishmaniasis: a report. Arch Hyg Sci 2013; 2: 48-54.
  7. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci 2008; 97: 2405-2425. https://doi.org/10.1002/jps.21179
  8. Eddaikra N, Ait-Oudhia K, Kherrachi I, Oury B, Moulti-Mati F, Benikhlef R, Harrat Z, Sereno D. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria. PLoS Negl Trop Dis 2018; 12: e0006310. https://doi.org/10.1371/journal.pntd.0006310
  9. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007; 14: 1153-1169. https://doi.org/10.2174/092986707780362862
  10. Rayman MP. Selenium and human health. Lancet 2012; 379:1256-1268. https://doi.org/10.1016/S0140-6736(11)61452-9
  11. Tapiero H, Townsend DM, Tew KD. The antioxidant role of selenium and seleno-compounds. Biomed Pharmacother 2003; 57:134-144. https://doi.org/10.1016/S0753-3322(03)00035-0
  12. Mahmoudvand H, Shakibaie M, Tavakoli R, Jahanbakhsh S, Sharifi I. In vitro study of leishmanicidal activity of biogenic selenium nanoparticles against Iranian isolate of sensitive and glucantime-resistant Leishmania tropica. Iran J Parasitol 2014; 9: 452-460.
  13. Beheshti N, Soflaei S, Shakibaie M, Yazdi MH, Ghaffarifar F, Dalimi A, Shahverdi AR. Efficacy of biogenic selenium nanoparticles against Leishmania major: In vitro and in vivo studies. J Trace Elem Med Biol 2013; 27: 203-207. https://doi.org/10.1016/j.jtemb.2012.11.002
  14. Soflaei S, Dalimi A, Abdoli A, Kamali M, Nasiri V, Shakibaie M, Tat M. Anti-leishmanial activities of selenium nanoparticles and selenium dioxide on Leishmania infantum. Comp Clin Path 2014; 23: 15-20. https://doi.org/10.1007/s00580-012-1561-z
  15. Debnath A, Kumar A. Structural and Functional significance of Niosome and Proniosome in Drug Delivery System. Int J Pharm and Eng 2015; 3: 621-637.
  16. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems - an overview. Adv Colloid Interface Sci 2012; 183: 46-54. https://doi.org/10.1016/j.cis.2012.08.002
  17. Riabi TR, Sharifi I, Miramin Mohammadi A, Khamesipour A, Hakimi Parizi M. Evaluation of a possible synergistic effect of meglumine antimoniate with paromomycin, miltefosine or allopurinol on in vitro susceptibility of Leishmania tropica resistant isolate. Iran J Parasitol 2013; 8: 396-401.
  18. Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci 1995; 58: 1-55. https://doi.org/10.1016/0001-8686(95)00242-I
  19. Koutsoni O, Barhoumi M, Guizani I, Dotsika E. Leishmania eukaryotic initiation factor (LeIF) inhibits parasite growth in murine macrophages. PLoS One 2014; 9: e97319. https://doi.org/10.1371/journal.pone.0097319
  20. Chandra D, Naik S. Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 2008; 154: 224-234. https://doi.org/10.1111/j.1365-2249.2008.03741.x
  21. Zhong M, Wang X, Wen J, Cai J, Wu C, Aly SM. Selection of reference genes for quantitative gene expression studies in the house fly (Musca domestica L.) using reverse transcription quantitative real-time PCR. Acta Biochim Biophys Sin (Shanghai) 2013; 45: 1069-1073. https://doi.org/10.1093/abbs/gmt111
  22. S SK, R K G, Ghosh M. Comparative in-silico genome analysis of Leishmania (Leishmania) donovani: a step towards its species specificity. Meta gene 2014; 2: 782-798. https://doi.org/10.1016/j.mgene.2014.10.003
  23. Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khashayarmanesh Z, Feizi E, Neghabi K, Abbasi A, Jaafari MR. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Exp Parasitol 2014; 143: 5-10. https://doi.org/10.1016/j.exppara.2014.04.013
  24. Ag Seleci D, Seleci M, Walter JG, Stahl F, Scheper T. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomater 2016; 2016: 1-13.
  25. Lobanov A V, Gromer S, Salinas G, Gladyshev VN. Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res 2006; 34: 4012-4024. https://doi.org/10.1093/nar/gkl541
  26. Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z. Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 2011; 103: 55-98.
  27. Zhang J, Wang H, Yan X, Zhang L. Comparison of short-term toxicity between Nano-Se and selenite in mice. Life Sci 2005; 76: 1099-1109. https://doi.org/10.1016/j.lfs.2004.08.015
  28. Wang H, Zhang J, Yu H. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: Comparison with selenomethionine in mice. Free Radic Biol Med 2007; 42: 1524-1533. https://doi.org/10.1016/j.freeradbiomed.2007.02.013
  29. de Souza CES, da Silva ARP, Gomez MCV, Rolom M, Coronel C, da Costa JGM, Sousa AK, Rolim LA, de Souza FHS, Coutinho HDM. Anti-Trypanosoma, anti-Leishmania and cytotoxic activities of natural products from Psidium brownianum Mart. ex DC. and Psidium guajava var. Pomifera analysed by LC-MS. Acta Trop 2017; 176: 380-384. https://doi.org/10.1016/j.actatropica.2017.09.009
  30. Martin-Montes A, Plano D, Martin-Escolano R, Alcolea V, Diaz M, Perez-Silanes S, Espuelas S, Moreno E, Marin C, Gutierrez-Sanchez R, Sanmartin C, Sanchez-Moreno M. Library of selenocompounds as novel agents against Leishmania species. Antimicrob Agents Chemother 2017; 61: 1-13.
  31. Olliaro PL. Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 2010; 23: 595-602. https://doi.org/10.1097/QCO.0b013e32833fca9d
  32. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006; 142: 1575-1579. https://doi.org/10.1001/archderm.142.12.1575
  33. Shamsi Meymandi S, Javadi A, Dabiri S, Shamsi Meymandi M, Nadji M. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. Arch Iran Med 2011; 14: 238-243.
  34. Farajzadeh S, Esfandiarpour I, Haghdoost AA, Mohammadi S, Mohebbi A, Mohebbi E4, Mostafavi M1. Comparison between combination therapy of oral terbinafine and cryotherapy versus systemic meglumine antimoniate and cryotherapy in cutaneous leishmaniasis: a randomized clinical trial. Iran J Parasitol 2015; 10: 1-8.
  35. Gannavaram S, Bhattacharya P, Ismail N, Kaul A, Singh R, Nakhasi HL. Modulation of innate immune mechanisms to enhance leishmania vaccine-induced immunity: role of coinhibitory molecules. Front Immunol 2016; 7: 187.
  36. Prajapati VK, Awasthi K, Gautam S, Yadav TP, Rai M, Srivastava ON, Sundar S. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother 2011; 66: 874-879. https://doi.org/10.1093/jac/dkr002
  37. Bogdan BC, Vodovotz Y, Nathan C. Macrophage deactivation by interleukln 10. J Exp Med 1991; 174: 1549-1555. https://doi.org/10.1084/jem.174.6.1549
  38. Ambit A, Fasel N, Coombs GH, Mottram JC. An essential role for the Leishmania major metacaspase in cell cycle progression. Cell Death Differ 2008; 15: 113-122. https://doi.org/10.1038/sj.cdd.4402232
  39. Raina P, Kaur S. Knockdown of LdMC1 and Hsp70 by antisense oligonucleotides causes cell-cycle defects and programmed cell death in Leishmania donovani. Mol Cell Biochem 2012; 359: 135-149. https://doi.org/10.1007/s11010-011-1007-y
  40. Lee N, Bertholet S, Debrabant A, Muller J, Duncan R, Nakhasi HL. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ 2002; 9: 53-64. https://doi.org/10.1038/sj.cdd.4400952
  41. Zalila H, Gonzalez IJ, El-Fadili AK, Delgado MB, Desponds C, Schaff C, Fasel N. Processing of metacaspase into a cytoplasmic catalytic domain mediating cell death in Leishmania major. Mol Microbiol 2011; 79: 222-239. https://doi.org/10.1111/j.1365-2958.2010.07443.x
  42. Debrabant A, Lee N, Bertholet S, Duncan R, Nakhasi HL. Programmed cell death in trypanosomatids and other unicellular organisms. Int J Parasitol 2003; 33: 257-267. https://doi.org/10.1016/S0020-7519(03)00008-0

Cited by

  1. New Amides Containing Selenium as Potent Leishmanicidal Agents Targeting Trypanothione Reductase vol.65, pp.1, 2020, https://doi.org/10.1128/aac.00524-20
  2. New Phosphoramidates Containing Selenium as Leishmanicidal Agents vol.65, pp.10, 2019, https://doi.org/10.1128/aac.00590-21
  3. Leishmaniasis and Trace Element Alterations: a Systematic Review vol.199, pp.10, 2021, https://doi.org/10.1007/s12011-020-02505-0